| Similar Articles |
|---|
 |
The Motley Fool
June 16, 2010
Jordan DiPietro |
Why These 3 Stocks Plunged Take a look at the most volatile stocks from yesterday: Smart Balance... La-Z-Boy... GameStop...   |
The Motley Fool
September 20, 2010
Jordan DiPietro |
Why Did These Stocks Plunge? Let's look at some stocks that plunged on Friday, and examine whether any logic justified their shift |
The Motley Fool
June 7, 2010
Jordan DiPietro |
The Market's Biggest Movers Takes a look at the most volatile stocks from the previous day and examines the logic behind the moves. |
The Motley Fool
June 22, 2010
Jordan DiPietro |
Why These 3 Stocks Plunged Take a look at the day's most volatile stocks. |
The Motley Fool
May 3, 2011
Brian Orelli |
Brakes Are Off at Dendreon Ramping up sales, one month at a time. |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
June 19, 2009
Brian Orelli |
Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk. |
The Motley Fool
March 2, 2011
Brian Orelli |
When Will Dendreon Make Money? Not for awhile ... it's a biotech thing. |
The Motley Fool
November 10, 2006
Brian Lawler |
Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note. |
The Motley Fool
November 16, 2007
Brian Lawler |
Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
May 10, 2005
Charly Travers |
Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in? |
The Motley Fool
March 13, 2008
Brian Lawler |
Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug. |
The Motley Fool
June 18, 2009
Daniel Harrison |
Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains. |
The Motley Fool
April 14, 2009
Brian Orelli |
Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge. |
The Motley Fool
January 17, 2007
Brian Lawler |
Dendreon in the Fast Lane The FDA speeds up review of Dendreon's leading drug candidate. Investors, take note. |
The Motley Fool
June 22, 2009
Jim Mueller |
Dendreon: Cash Out or Keep Riding Up? Given Dendreon's rise this year and Provenge's prospects, what should a prudent investor do? |
The Motley Fool
September 28, 2010
Brian Orelli |
It's Up! It's Down! It's Dendreon! The joys of biotech. |
The Motley Fool
March 19, 2007
Brian Lawler |
Is Dendreon Doomed? A pivotal FDA regulatory meeting approaches for the development-stage pharma. Investors, take note. |
The Motley Fool
September 22, 2010
Brian Orelli |
A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead. |
The Motley Fool
December 5, 2011
Alyce Lomax |
This Stock Faces Destination Destruction Barnes & Noble is going nowhere but down. |
The Motley Fool
August 18, 2010
Travers & Greer |
Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon? |
The Motley Fool
July 1, 2011
Brian Orelli |
Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic. |
The Motley Fool
April 17, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Dyax... SLM Corp... IPSCO... Dendreon... Manor Care... |
The Motley Fool
January 7, 2011
Brian Orelli |
Dendreon Heads Across the Pond A pathway to Provenge approval in the EU. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
The Motley Fool
November 18, 2010
Brian Orelli |
Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge. |
The Motley Fool
June 21, 2010
Rick Aristotle Munarriz |
Price War for Apple and Amazon? Barnes & Noble slashes the price of its e-book reader. |
The Motley Fool
October 31, 2008
Brian Orelli |
World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
The Motley Fool
June 1, 2010
Brian Orelli |
Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile. |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
The Motley Fool
April 3, 2007
Brian Lawler |
Dendreon's Positive Panel Surprise Shares of the drugmaker jump after a FDA advisory panel finds in favor of its lead cancer compound. |
The Motley Fool
July 21, 2009
Alyce Lomax |
Barnes & Noble Strikes Back The bricks-and-mortar bookstore giant takes a page from Amazon.com. |
The Motley Fool
August 5, 2010
Surojit Chatterjee |
Barnes & Noble Is on Sale but May Find Few Takers Is the pressure from e-readers and e-books too much? |
The Motley Fool
June 1, 2007
Brian Lawler |
Dendreon Gains. Why? Shares of the biopharma rise after it announces already expected news. |
The Motley Fool
September 25, 2009
Brian Orelli |
Dendreon Struts Its Stuff Like a peacock without any FDA-approved feathers. |
The Motley Fool
March 11, 2011
Brian Orelli |
Sales Can Quadruple, More to Come Dendreon is still supply-constrained, but less than before. |
The Motley Fool
May 16, 2007
Brian Lawler |
GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note. |
The Motley Fool
August 18, 2010
Carl Bagh |
Barnes & Noble Attempts to Stay Afloat The bookseller looks for strategic partners in the e-book game. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
May 9, 2011
Katie Spence |
In the Battle of E-Readers, Will Barnes & Noble Surrender? Is the bookselling superstore headed for the paper shredder? |
The Motley Fool
May 18, 2004
Nathan Slaughter |
Barnes & Noble's Bestselling Q1 The leading bookseller sees a 22% surge in revenues. |
The Motley Fool
August 31, 2010
Brian Orelli |
What Is Dendreon Worth? Now that's a good question, isn't it? |
The Motley Fool
August 10, 2011
Jim Mueller |
Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here. |
The Motley Fool
September 13, 2007
Brian Lawler |
Don't Bet on the Dendreon Lawsuit A patient advocacy group files a lawsuit attempting to usher Dendreon's prostate cancer drug Provenge onto the market after the FDA has withheld approval. Investors should take note. |
The Motley Fool
May 9, 2007
Brian Lawler |
Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note. |
The Motley Fool
September 1, 2010
Brian Orelli |
Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge. |
The Motley Fool
April 5, 2010
Brian Orelli |
1 Month to Go! Is Dendreon a Buy? Only if you understand the risks. |
